The rule could widen which peptides pharmacies may compound, after FDA advisers narrowly backed several in July despite concerns from agency scientists.
Recap by typeshit. Full story at Yahoo.
Alicia Butterfield claims Anthem denied her Zepbound once the drug got her below morbid obesity. A Los Angeles judge stayed her case pending arbitration.
STAT
Members of Congress from both parties want the FDA to stop imports of copycat versions of Eli Lilly's experimental obesity drug, which is still in trials.
Bloomberg says the boom in GLP-1 use has opened a risky trade in weight loss drugs brought into Brazil illegally.
The pharmacy boards group, per InsideHealthPolicy, ties reported deaths linked to retatrutide to weak enforcement against gray-market peptide sellers.
B&T reports the agency Wavemaker has taken over media duties for Novo Nordisk, the company behind Ozempic and Wegovy.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Loading…